Beta Bionics (NASDAQ:BBNX) Upgraded at Wells Fargo & Company

Beta Bionics (NASDAQ:BBNX) was upgraded by Wells Fargo & Company to a “strong-buy” rating in a research note issued to investors on Wednesday, Zacks reports.

Several other equities analysts have also commented on BBNX. Leerink Partners upped their price target on shares of Beta Bionics from $24.00 to $27.00 and gave the stock an “outperform” rating in a research report on Monday, September 14th. UBS Group reissued a “buy” rating and set a $25.00 price target on shares of Beta Bionics in a research report on Tuesday, September 15th. The Goldman Sachs Group upped their price target on Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Robert W. Baird lifted their price objective on Beta Bionics from $14.00 to $16.00 and gave the company a “neutral” rating in a research note on Tuesday, September 15th. Finally, Bank of America boosted their target price on Beta Bionics from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Tuesday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Beta Bionics has an average rating of “Moderate Buy” and an average price target of $22.45.

Beta Bionics Trading Down 2.7%

Shares of BBNX stock opened at $22.19 on Wednesday. The company has a market cap of $998.33 million, a P/E ratio of -13.45 and a beta of 3.37. The firm has a fifty day moving average price of $17.98 and a 200 day moving average price of $14.29. Beta Bionics has a 12 month low of $8.80 and a 12 month high of $32.71.

Beta Bionics (NASDAQ:BBNX) last announced its earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.09. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. The business had revenue of $32.01 million during the quarter. On average, equities analysts forecast that Beta Bionics will post -2.06 EPS for the current year.

Insider Transactions at Beta Bionics

In other Beta Bionics news, insider Mark Hopman sold 36,870 shares of Beta Bionics stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $18.46, for a total transaction of $680,620.20. Following the sale, the insider directly owned 87,157 shares in the company, valued at $1,608,918.22. The trade was a 29.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Russell sold 4,221 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total value of $80,663.31. Following the transaction, the insider owned 169,628 shares of the company’s stock, valued at approximately $3,241,591.08. This trade represents a 2.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 107,327 shares of company stock worth $2,070,421 over the last three months. Insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd lifted its holdings in Beta Bionics by 1,075.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock worth $61,000 after buying an additional 1,818 shares during the last quarter. Legal & General Group Plc bought a new position in Beta Bionics in the second quarter worth about $62,000. ProShare Advisors LLC acquired a new position in Beta Bionics in the fourth quarter valued at approximately $217,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Beta Bionics during the 2nd quarter worth approximately $172,000. Finally, Values First Advisors Inc. raised its position in shares of Beta Bionics by 35.1% during the 1st quarter. Values First Advisors Inc. now owns 47,551 shares of the company’s stock worth $476,000 after purchasing an additional 12,360 shares during the period.

Key Stories Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Beta Bionics announced a partnership with Senseonics to integrate its iLet Bionic Pancreas and mint automated insulin-delivery systems with Senseonics’ Eversense 365 continuous glucose monitor. The combined iLet-Eversense system is expected to launch commercially in the fourth quarter of 2026, potentially expanding customer choice and strengthening BBNX’s competitive position in automated diabetes management. Beta Bionics Announces Agreement to Integrate Its Systems with Senseonics’ Eversense 365
• Neutral Sentiment: Multiple law firms publicized the same pending securities class action against Beta Bionics. The proposed class covers investors who purchased shares from July 30, 2025, through February 24, 2026, with November 3, 2026, set as the lead-plaintiff deadline. The notices themselves largely repeat existing litigation information, but they increase visibility around the claims and potential legal costs. BBNX Investor Deadline and Class Action Notice
• Negative Sentiment: The lawsuit alleges Beta Bionics failed to disclose or adequately describe FDA concerns, including a June 2025 Form 483 and more than 18,000 iLet complaints. The allegations claim subsequent disclosures about the FDA’s concerns and medical-device safety led to a sharp decline in BBNX shares. These claims have not been proven, but the litigation creates regulatory, reputational and financial uncertainty. Johnson Fistel BBNX Investor Alert
• Negative Sentiment: Director Christy Jones sold 6,430 shares for approximately $147,890, reducing her holdings by about 24.7%. The transaction was made under a pre-arranged Rule 10b5-1 trading plan, which somewhat limits its value as a discretionary bearish signal; however, it adds to reported insider-selling activity and there have been no recent open-market insider purchases highlighted in the coverage. SEC Form 4 Filing

Beta Bionics Company Profile

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.